- Report
- March 2023
- 653 Pages
Global
From €4706EUR$4,950USD£4,036GBP
- Report
- June 2021
- 378 Pages
Global
From €4706EUR$4,950USD£4,036GBP
- Report
- May 2021
- 174 Pages
Global
From €4706EUR$4,950USD£4,036GBP
- Report
- March 2020
- 245 Pages
Global
From €3327EUR$3,500USD£2,854GBP
- Report
- May 2024
- 194 Pages
From €3208EUR$3,374USD£2,751GBP
€3564EUR$3,749USD£3,057GBP
- Report
- August 2021
- 131 Pages
Global
From €5656EUR$5,950USD£4,852GBP
- Report
- February 2023
- 328 Pages
Global
From €4753EUR$5,000USD£4,077GBP
- Report
- August 2023
- 78 Pages
Egypt
From €3327EUR$3,500USD£2,854GBP
- Report
- July 2022
- 100 Pages
Global
From €2614EUR$2,750USD£2,242GBP
- Report
- July 2022
- 100 Pages
Global
From €2614EUR$2,750USD£2,242GBP
- Report
- July 2022
- 100 Pages
Global
From €2614EUR$2,750USD£2,242GBP
- Report
- April 2023
- 111 Pages
Global
From €4516EUR$4,750USD£3,873GBP
- Report
- April 2023
- 75 Pages
South Africa
From €4516EUR$4,750USD£3,873GBP
- Report
- June 2022
- 115 Pages
Global
From €4516EUR$4,750USD£3,873GBP
- Report
- May 2020
- 60 Pages
North America
From €4516EUR$4,750USD£3,873GBP
- Report
- May 2020
- 85 Pages
Europe
From €4516EUR$4,750USD£3,873GBP
- Report
- January 2023
- 96 Pages
From €1996EUR$2,100USD£1,712GBP
€2852EUR$3,000USD£2,446GBP
- Report
- January 2023
- 104 Pages
North America
From €1996EUR$2,100USD£1,712GBP
€2852EUR$3,000USD£2,446GBP
- Report
- January 2023
- 94 Pages
Middle East, Africa
From €1996EUR$2,100USD£1,712GBP
€2852EUR$3,000USD£2,446GBP
- Report
- January 2023
- 111 Pages
Asia Pacific
From €1996EUR$2,100USD£1,712GBP
€2852EUR$3,000USD£2,446GBP
Within the field of cardiovascular devices, Left Ventricular Assist Devices (LVADs) comprise a specialized segment aimed at supporting patients with advanced heart failure. LVADs are mechanical pumps that are implanted to assist the failing left ventricle, the main pumping chamber of the heart, by maintaining adequate blood flow throughout the body. The utility of LVADs extends from serving as a bridge to heart transplantation, to being a destination therapy for patients who are not candidates for a transplant. As technology has advanced, LVADs have become more compact and reliable, leading to improvements in patient outcomes and quality of life. The market for LVADs is influenced by several factors, including technological advancements, an aging population, and the prevalence of heart failure. Collaboration between medical device manufacturers and the healthcare community is essential in driving innovation and addressing the needs of the patient population.
Some key players in the LVAD market include Abbott Laboratories, which offers the HeartMate product line, Medtronic, known for its HeartWare HVAD system, and Berlin Heart, which provides the INCOR and EXCOR devices. Other companies active in this space are Abiomed, which has developed the Impella heart pump, and Jarvik Heart, maker of the Jarvik 2000 LVAD. Show Less Read more